| Background: Gastric carcinoma is one of the most common malignancies.The forth cause of cancer incidence rate and the second leading cause of cancer mortality in the world.In our country,the morbidity and mortality account for the first and the second cause of malignant tumor respectively.In recent years,the incidence of gastric cancer is decreasing worldwide.Advanced adenocarcinoma of the stomach continues to have a poor prognosis, with a median survival of 6 months. Surgical resection is the mainstay of treatment and can cure patients with early-stage cancer.However, over 70% of advanced gastric carcinoma patients experience postsurgical recurrence. Systemic chemotherapy is an important means of gastric carcinoma, especially no surgical indications of advanced gastric carcinoma, Although various chemotherapeutic drugs have been used for the treatment of gastric carcinoma, they are generally not effective either when used alone or in combination therapy with other drugs. Hence,for increasing therapeutics effect,searching for new therapeutics targets for patients of gastric carcinoma is a warm spots. Recent studies have found that cyclooxygenase (COX) has a high expression in many tumors, which has attracted wide attention. Cyclooxygenase is an important rate-limiting enzyme, it can catalysis arachidonic acid into prostaglandins, there are two main subtypes: constitive COX-1 and inducible COX-2. Large number of studies show that COX-2 has a close relationship with gastric carcinoma. The Her-2 protein is a 185-kDa transmembrane tyrosine kinase (TK) receptor and a member of the epidermal growth factor receptors (EGFRs) family. Her-2 play an important role in proliferation and differentiation of normal cell.But its inadequacy activation has a relationship with many tumors. The correlation of COX-2 and Her-2/neu in gastric carcinoma tissues has a less research. In our study, the expression of COX-2 protein and Her-2/neu proteins were detected by immunohistochemistry in gastric carcinoma, to explore the correlation between COX-2 and Her-2/neu and their clinical meanings.To find their effection to prognosis of gastric carcinoma.Objective: To study the correlation of cyclooxygenase-2 (COX-2) and Her-2/neu in gastric carcinoma and their relationship with clinicopathologic features . To find their effection to prognosis of gastric carcinoma.Methods: The expression of COX-2 and Her-2/neu in 419 cases of gastric carcinoma was detected by immunohistochemical technique. The results were analysed by SPSS 13. 0.Results: In 419 cases of gastric carcinoma the positive rate of COX-2 was 66.35%(278/419), No correlation was found between increased COX-2 and the tumor size , diferentiation , lymph node metastasis , clinical stage,distant metastasis and depth of invasion of gastric carcinoma( P>0.05) .Its expression was correlated with survival time ( P<0.05). The positive rate of Her-2/neu was 13.6%(57/419).Her-2/neu expression was correlated with diferentiation and survival time. ( P<0.05) . No correlation was found between increased Her-2/neu and the tumor size, lymph node metastasis , clinical stage,distant metastasis and depth of invasion of gastric carcinoma( P>0.05) . The expression of Her-2/neu was significantly correlated with COX-2 ( P<0.025) .Conclusion: The expression of COX-2 in gastric carcinoma are high, Her-2/neu expression was correlated with diferentiation. The expression of Her-2/neu was significantly correlated with COX-2 . COX-2 is possible an important therapeutics target for patients of gastric carcinoma whose Her-2/neu are positive. The expression of COX-2 and Her-2/neu was correlated with survival time.They can be used to evaluate the prognosis of gastric carcinoma.
|
PDF Full Text Request